A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Hematopoietic Malignancies
Lymphoma
Non-Hodgkin Lymphoma
Unknown Primary
18 Years and older, Male and Female
LYL314-102 (primary)
NCI-2026-00303
Summary
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting
CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in
patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
Objectives
PiNACLE-H2H is a Phase 3 randomized controlled trial comparing the efficacy and safety of
rondecabtagene autoleucel (ronde-cel, formerly known as LYL314) against the currently
approved cluster of differentiation (CD)19 chimeric antigen receptor (CAR) T-cell
therapies (axicabtagene ciloleucel [axi-cel] or lisocabtagene maraleucel [liso-cel]), in
patients with aggressive LBCL that has relapsed or is refractory to first-line anti-CD20
antibody and anthracycline-containing chemotherapy.
Patients will be randomized (1:1) before leukapheresis to receive either:
- Ronde-cel; or
- Investigator's choice of axi-cel or liso-cel
Most patients who receive currently approved CD19-directed CAR T-cell therapies,
including axi-cel and liso-cel, still experience progressive disease, often due to
mechanisms such as CD19 antigen loss or T-cell exhaustion.
Ronde-cel is a novel, autologous, dual-targeting CD19/CD20 CAR T-cell product candidate
enriched for CD62L-positive naïve and central memory T cells, which are associated with
enhanced proliferation capacity and persistence. Ronde-cel is an "OR"-gated CAR construct
that can fully activate upon recognition of either CD19 or CD20, aiming to improve
durability of response despite antigen heterogeneity.
Approximately 400 participants will be enrolled. CAR T-cell therapy in both arms will be
administered as a single intravenous infusion following fludarabine and cyclophosphamide
lymphodepletion. Participants will be followed for 3 years for safety and efficacy, with
long-term follow-up extending to 15 years.
Eligibility
- CAR T cell naïve and eligible to receive a CD19 CART-cell therapy
- Histologically confirmed large B-cell lymphoma, including the following types defined by (WHO 2022) or International Consensus Classification (2022)
- Diffuse large B-cell lymphoma (DLBCL)
- Transformations of indolent B-cell lymphomas (excluding Richter's transformation)
- DLBCL/High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements
- High-grade B-cell lymphoma (HGBCL) not otherwise specified (HGBCL NOS)
- Primary mediastinal large B-cell lymphoma (PMBCL)
- Grade 3B follicular lymphoma/large cell follicular lymphoma (FL3B)
- Relapsed or refractory disease after anti-CD20 antibody and anthracycline-containing first-line chemoimmunotherapy
- Measurable disease by presence of [18F]-fluorodeoxyglucose PET/CT positive lesion during Screening per Lugano Criteria
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Adequate hematological, renal, hepatic, pulmonary, and cardiac function Key
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.